$1.87
6.03%
Nasdaq, Sep 12, 10:17 pm CET
ISIN
US29446K1060
Symbol
EQ

Equillium, Inc. Stock price

$1.87
+0.94 100.19% 1M
+1.12 149.33% 6M
+1.12 149.93% YTD
+1.00 114.94% 1Y
-0.41 17.98% 3Y
-3.85 67.31% 5Y
-12.13 86.64% 10Y
-12.13 86.64% 20Y
Nasdaq, Closing price Fri, Sep 12 2025
-0.12 6.03%
ISIN
US29446K1060
Symbol
EQ
Industry

Key metrics

Basic
Market capitalization
$111.3m
Enterprise Value
$99.8m
Net debt
positive
Cash
$11.5m
Shares outstanding
35.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.7 | -
EV/Sales
6.0 | -
EV/FCF
negative
P/B
22.0
Financial Health
Equity Ratio
74.5%
Return on Equity
-42.3%
ROCE
-396.0%
ROIC
530.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$16.6m | $0.0
EBITDA
$-20.3m | -
EBIT
$-20.5m | $-34.4m
Net Income
$-20.2m | $-31.3m
Free Cash Flow
$-22.2m
Growth (TTM | estimate)
Revenue
-61.2% | -100.0%
EBITDA
-112.3% | -
EBIT
-110.8% | -315.7%
Net Income
-142.7% | -287.5%
Free Cash Flow
-40.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-122.9% | -
EBIT
-123.7%
Net
-122.0% | -
Free Cash Flow
-133.8%
More
EPS
$-0.6
FCF per Share
$-0.6
Short interest
4.4%
Employees
35
Rev per Employee
$1.2m
Show more

Is Equillium, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Equillium, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Equillium, Inc. forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Equillium, Inc. forecast:

Buy
73%
Hold
27%

Financial data from Equillium, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
17 17
61% 61%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 10 10
26% 26%
61%
- Research and Development Expense 27 27
31% 31%
162%
-20 -20
112% 112%
-123%
- Depreciation and Amortization 0.14 0.14
8% 8%
1%
EBIT (Operating Income) EBIT -20 -20
111% 111%
-124%
Net Profit -20 -20
143% 143%
-122%

In millions USD.

Don't miss a Thing! We will send you all news about Equillium, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Equillium, Inc. Stock News

Neutral
Business Wire
12 days ago
LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Positive
The Motley Fool
12 days ago
While last month ended up being a decent one for the Nasdaq Composite, it was downright fantastic for a handful of Nasdaq-listed names. Here's a rundown of the Nasdaq Composite's five-best performing stocks that blew the index's 1.6% August gain out of the water.
Neutral
Business Wire
17 days ago
LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium to Participate in the Cantor Global Healthcare Conference 2025.
More Equillium, Inc. News

Company Profile

Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.

Head office United States
CEO Bruce Steel
Employees 35
Founded 2017
Website www.equilliumbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today